Your search for baricitinib returned 4 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Lea Eslava-Kim, PharmD remove

Your search for baricitinib returned 4 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Oral Baricitinib Evaluated in RA Unresponsive to Conventional DMARDs

Eli Lilly and Incyte announced positive data from the pivotal study, RA-BEYOND, evaluating baricitinib vs. placebo for the treatment of rheumatoid arthritis (RA). Study findings were presented at the Annual European Congress of Rheumatology (EULAR 2016) in London.
Drugs in the Pipeline

FDA to Review Once-Daily Oral RA Tx

Eli Lilly and Incyte announced that the New Drug Application (NDA) for once-daily oral baricitinib has been submitted to the Food and Drug Administration (FDA) for the treatment of moderately-to-severely active rheumatoid arthritis (RA).
Drugs in the Pipeline

Study: Baricitinib Superior to Conventional DMARD

Eli Lilly and Incyte announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib for the treatment of patients with moderately-to-severely active rheumatoid arthritis (RA).